ResMed (BSP:R1MD34) Cyclically Adjusted Revenue per Share: R$36.56 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:R1MD34 ResMed Inc BSP:R1MD34
90 GF Score
Price R$243.85
GF Value R$282.14
! 1 Warning Sign
View Full Analysis

What is ResMed Cyclically Adjusted Revenue per Share?

ResMed BSP:R1MD34 90 Cyclically Adjusted Revenue per Share is R$36.56 as of Jun. 2026. GuruFocus rates BSP:R1MD34 with a GF Score™ of 90/100 and a GF Value™ of R$282.14. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ResMed's adjusted revenue per share for the three months ended in Jun. 2026 was R$12.921. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$36.56 for the trailing ten years ended in Jun. 2026.

During the past 12 months, ResMed's average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ResMed was 26.90% per year. The lowest was 11.20% per year. And the median was 14.15% per year.

As of today (2026-08-21), ResMed's current stock price is R$243.85. ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was R$36.56. ResMed's Cyclically Adjusted PS Ratio of today is 6.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ResMed was 18.37. The lowest was 6.15. And the median was 9.72.


ResMed  (BSP:R1MD34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ResMed's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=243.85/36.56
=6.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ResMed was 18.37. The lowest was 6.15. And the median was 9.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ResMed Cyclically Adjusted Revenue per Share Related Terms


ResMed Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ResMed's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Cyclically Adjusted Revenue per Share Chart

ResMed Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.17 27.70 34.43 36.02 36.56

ResMed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.02 35.23 37.69 36.40 36.56

BSP:R1MD34 vs MDLN, WST, COO: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted PS Ratio falls into.


BSP:R1MD34
90GF Score
ResMed Inc BSP:R1MD34
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=12.921/333.9520*333.9520
=12.921

Current CPI (Jun. 2026) = 333.9520.

ResMed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.664 241.428 3.685
201612 3.130 241.432 4.329
201703 2.817 243.801 3.859
201706 3.213 244.955 4.380
201709 2.858 246.819 3.867
201712 3.443 246.524 4.664
201803 3.368 249.554 4.507
201806 4.075 251.989 5.400
201809 4.195 252.439 5.550
201812 4.379 251.233 5.821
201903 4.405 254.202 5.787
201906 4.690 256.143 6.115
201909 4.834 256.759 6.287
201912 5.189 256.974 6.743
202003 6.452 258.115 8.348
202006 6.837 257.797 8.857
202009 6.948 260.280 8.915
202012 7.027 260.474 9.009
202103 7.443 264.877 9.384
202106 7.512 271.696 9.233
202109 8.124 274.310 9.890
202112 8.604 278.802 10.306
202203 7.318 287.504 8.500
202206 7.849 296.311 8.846
202209 8.467 296.808 9.527
202212 9.196 296.797 10.347
202303 9.867 301.836 10.917
202306 9.223 305.109 10.095
202309 9.228 307.789 10.012
202312 9.654 306.746 10.510
202403 10.106 312.332 10.806
202406 11.163 314.175 11.866
202409 11.486 315.301 12.165
202412 13.259 315.605 14.030
202503 12.631 319.799 13.190
202506 12.708 322.561 13.157
202509 12.190 324.800 12.533
202512 13.258 324.054 13.663
202603 12.842 330.213 12.987
202606 12.921 333.952 12.921

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of R$36.56 mean?
ResMed (BSP:R1MD34) has a Cyclically Adjusted Revenue per Share of R$36.56 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ResMed and its competitors.
Is ResMed's Cyclically Adjusted Revenue per Share too high?
ResMed's current Cyclically Adjusted Revenue per Share is R$36.56. Overall, ResMed has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does ResMed's Cyclically Adjusted Revenue per Share compare to MDLN and WST?
ResMed's Cyclically Adjusted Revenue per Share of R$36.56 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ResMed and its competitors. ResMed's current Cyclically Adjusted Revenue per Share is R$36.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
ResMed (BSP:R1MD34) has a current Cyclically Adjusted Revenue per Share of R$36.56. The stock's GF Value™ is R$282.14, compared to a current price of R$243.85 — trading 13.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is R$36.56. ResMed's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ResMed (BSP:R1MD34), the current Cyclically Adjusted Revenue per Share is R$36.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (BSP:R1MD34) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of R$243.85 is trading 13.6% below its estimated GF Value™ of R$282.14.

Key valuation signals for BSP:R1MD34:

  • Cyclically Adjusted Revenue per Share: R$36.56
  • GF Value™: R$282.14 vs. price of R$243.85 (13.6% below fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the BSP:R1MD34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
90GF Score

Get the complete analysis for BSP:R1MD34

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$243.85
Price
R$282.14
GF Value